Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Gabelli lowered their FY2022 earnings estimates for shares of Hologic in a research report issued to clients and investors on Monday. Gabelli analyst S. Wojda now forecasts that the medical equipment provider will earn $3.05 per share for the year, down from their previous forecast of $3.25.
Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The business had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. During the same period in the previous year, the business earned $0.52 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis.
Hologic (NASDAQ:HOLX) traded up $0.29 during trading on Tuesday, reaching $38.04. The company had a trading volume of 4,473,200 shares, compared to its average volume of 3,002,262. Hologic has a twelve month low of $35.33 and a twelve month high of $46.80. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. The stock has a market capitalization of $10,438.97, a PE ratio of 10.04, a price-to-earnings-growth ratio of 1.71 and a beta of 0.77.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. Parnassus Investments CA bought a new position in shares of Hologic in the 3rd quarter worth approximately $277,062,000. Point72 Asset Management L.P. bought a new position in shares of Hologic in the 3rd quarter worth approximately $39,041,000. Pictet Asset Management Ltd. raised its position in shares of Hologic by 50.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 2,912,338 shares of the medical equipment provider’s stock worth $106,854,000 after acquiring an additional 974,325 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Hologic by 16.8% in the 3rd quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock worth $214,885,000 after acquiring an additional 844,426 shares in the last quarter. Finally, First Trust Advisors LP raised its position in shares of Hologic by 161.9% in the 3rd quarter. First Trust Advisors LP now owns 924,576 shares of the medical equipment provider’s stock worth $33,923,000 after acquiring an additional 571,512 shares in the last quarter. 93.84% of the stock is owned by institutional investors and hedge funds.
In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.88% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.